PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers

Y. Kogan, M. Kleiman, S. Shannon, M. Elishmereni, E. Taub, L. Aptekar, R. Brenner, R. Berger, H. Nechushtan, Z. Agur. 176P PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers. Journal of Thoracic Oncology , Volume 13 , Issue 4 , S105

Link to the Poster

Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data

Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate. 2016;76(1):48-57. doi: 10.1002/pros.23099. PubMed PMID: 26419619.

Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein

Kheifetz, Y., Elishmereni, M., Agur, Z. Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein. J Pharmacokinet Pharmacodyn 2014 41(5) pp. 479-491., PMID: 25231819

Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration

Agur Z, Elishmereni M, Kheifetz Y. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med. 2014;6(3):239-53. doi: 10.1002/wsbm.1263. PubMed PMID: 24604755.

Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Vainas O, Ariad S, Amir O, Mermershtain W, Vainstein V, Kleiman M, Inbar O, Ben-Av R, Mukherjee A, Chan S, Agur Z. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. Br J Cancer. 2012;107(5):814-22. Epub 2012/07/21. doi: bjc2012316 [pii], 10.1038/bjc.2012.316. PubMed PMID: 22814580; PMCID: 3425973.

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization

Jager E., van der Velden V.H., Te Marvelde JG., Walter R.B., Agur Z., Vainstein V.
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS one 2011 6(9) e24265

An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers

Elishmereni M, Kheifetz Y, Søndergaard H, Viig R. O, Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers.PLoS Computational Biology 2011 7(9) e1002206

From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology

Agur Z. From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology, Future Oncology, 2010;6(6), (pp. 917-27).

Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model

Gorelik B., Ziv I., Shohat R., Wick M., Hankins D., Sidransky D., Agur Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008;68(21), (pp. 9033–9040).

Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study

Agur Z., Elishmereni M., Kogan Y., Kheiffetz Y., Ziv I., Shoham M., and Vainstein V. "Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study" in 'Preclinical Development Handbook', Shayne Gad Ed., John Wiley & Sons, USA. 2008, pp 1229-1266.

Optimizing chemotherapy scheduling using local search heuristics

Agur Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics, Operations Research. 2006 Sep;54 (5) 2006 (pp.829-846).

Biomathematics in the development of personalized medicine in oncology

Agur Z. Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006 Feb;2 (1):39-42.

The Cross-Entropy Method for Continuous Multi-Extremal Optimization
Kroese D., P., Porotsky S., Rubinstein R., Y. The Cross-Entropy Method for Continuous Multi-Extremal Optimization. Methodol. Comput. Appl. Probab. Vol. 8 No. 3, 2006 (p.383–407) 
The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model

Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 2005;234(3):311-27. PubMed PMID: 15784267.